2d:I[856015,["/_next/static/immutable/chunks/1xzisbplk9czp.js","/_next/static/immutable/chunks/3j2i1faptc_-9.js","/_next/static/immutable/chunks/0fma7nlq6immz.js","/_next/static/immutable/chunks/08tq8rmv423j5.js","/_next/static/immutable/chunks/1chr5wkk3j58k.js","/_next/static/immutable/chunks/37kmmh_zm4dov.js","/_next/static/immutable/chunks/311zvdjfxff-f.js","/_next/static/immutable/chunks/1a_hqhrsle_n_.js"],"default"] 2e:T4d33,

Summary Table

Feature	Detail
Risk Factors	Long-standing diabetes mellitus (duration is the strongest risk factor), poor glycemic control (elevated HbA1c), hypertension, hyperlipidemia, pregnancy, nephropathy/proteinuria
Etiology	Chronic hyperglycemia causing microvascular damage to retinal capillaries through non-enzymatic glycosylation, sorbitol accumulation, and oxidative stress
Patient Presentation	Often asymptomatic in early stages; progressive painless vision loss, floaters, or sudden visual field defects in advanced disease
Classic Physical Exam	Fundoscopic findings: microaneurysms (earliest clinical sign), dot-and-blot hemorrhages, hard exudates, cotton-wool spots, neovascularization (proliferative stage)
Key Diagnostic Results	Fundoscopic exam and fluorescein angiography showing microaneurysms, capillary non-perfusion, or neovascularization; OCT for macular edema
Management	Strict glycemic and blood pressure control; anti-VEGF intravitreal injections for diabetic macular edema and proliferative disease; panretinal photocoagulation for proliferative diabetic retinopathy
Keywords	"Painless vision loss in a diabetic," "microaneurysms on fundoscopy," "neovascularization of the disc," "cotton-wool spots," "dot-and-blot hemorrhages"

1. Pathophysiology

Chronic hyperglycemia is the fundamental driver of retinal microvascular injury. Elevated blood glucose triggers several parallel biochemical pathways that converge on endothelial cell damage.

The polyol (sorbitol) pathway becomes overactive when intracellular glucose is shunted into aldose reductase, converting glucose to sorbitol. Sorbitol accumulates within pericytes and endothelial cells because it cannot freely cross cell membranes. This osmotic stress leads to pericyte loss, which is the earliest histological change in diabetic retinopathy. Pericytes normally provide structural support to capillary walls, so their loss weakens the vessel wall and produces focal outpouchings known as microaneurysms.

Simultaneously, non-enzymatic glycosylation of basement membrane proteins causes the capillary basement membrane to thicken. This thickening impairs oxygen and nutrient diffusion, creating localized retinal ischemia. The ischemic retina responds by upregulating vascular endothelial growth factor (VEGF), which drives the formation of fragile new blood vessels (neovascularization). These new vessels lack normal structural integrity, making them prone to hemorrhage and fibrosis.

The protein kinase C (PKC) pathway is also activated by hyperglycemia, increasing vascular permeability and promoting leukocyte adhesion. This explains the leakage of plasma lipoproteins into the retina, which deposits as hard exudates (yellow, waxy deposits with sharp borders). When ischemia is severe enough to cause nerve fiber layer infarction, the result is cotton-wool spots (soft, fluffy white lesions representing focal axoplasmic flow interruption).

Understanding this cascade clarifies the entire clinical spectrum: early disease is characterized by vascular leakage and weakness (non-proliferative), while advanced disease is driven by ischemia-induced neovascularization (proliferative).

2. Classification and Clinical Manifestation

Stage	Fundoscopy	Symptoms	Mechanism
Mild Non-Proliferative (NPDR)	Microaneurysms only	Asymptomatic	Pericyte loss, focal capillary wall weakness
Moderate NPDR	Microaneurysms + dot-and-blot hemorrhages + hard exudates + cotton-wool spots (fewer than severe criteria)	Usually asymptomatic	Progressive capillary leakage and focal ischemia
Severe NPDR (Preproliferative)	Any one of the "4-2-1 rule": hemorrhages in all 4 quadrants, venous beading in 2+ quadrants, or intraretinal microvascular abnormalities (IRMA) in 1+ quadrant	May remain asymptomatic or mild blurring	Widespread retinal ischemia, high risk of progressing to proliferative disease
Proliferative Diabetic Retinopathy (PDR)	Neovascularization of the disc (NVD) or elsewhere (NVE), vitreous hemorrhage, tractional retinal detachment, neovascular glaucoma	Floaters, sudden painless vision loss, visual field defects	VEGF-driven new vessel formation from severely ischemic retina
Diabetic Macular Edema (DME)	Retinal thickening or hard exudates within 1 disc diameter of the fovea; can occur at any stage	Central vision loss, distortion	Breakdown of the blood-retinal barrier with fluid accumulation at the macula

The 4-2-1 rule for severe NPDR is a classic testing target. Any single criterion being met qualifies the patient as having severe NPDR, which carries approximately a 50% risk of progression to PDR within one year.

A critical point: DME is not a stage in the NPDR-to-PDR progression. It is a separate process that can coexist with any stage and is the most common cause of vision loss in diabetic patients overall.

3. Diagnostic Workup

Test	Role	Key Findings
Dilated fundoscopic exam	Best initial test and primary screening tool	Microaneurysms, hemorrhages, exudates, neovascularization
Fluorescein angiography	Most accurate test for assessing vascular pathology	Microaneurysm leakage, capillary non-perfusion zones, neovascularization highlighted by dye leakage
Optical coherence tomography (OCT)	Best test for evaluating macular edema	Retinal thickening, intraretinal/subretinal fluid at the macula
Fundus photography	Documentation and screening (including teleophthalmology)	Baseline and serial comparison of retinal changes
HbA1c, lipid panel, blood pressure	Systemic risk assessment	Guides intensity of medical optimization

The dilated fundoscopic exam is the cornerstone of diagnosis and the recommended screening tool for all diabetic patients. Screening should begin 5 years after diagnosis in Type 1 diabetes and at the time of diagnosis in Type 2 diabetes (because Type 2 often has years of undiagnosed hyperglycemia preceding the formal diagnosis). After the initial screen, examinations are repeated annually, though patients with no retinopathy and good glycemic control may be screened every 2 years per updated guidelines.

Fluorescein angiography is ordered when the clinical picture requires further characterization. Fluorescein dye is injected intravenously and photographed as it transits the retinal vasculature. Microaneurysms appear as punctate hyperfluorescent dots. Areas of capillary dropout appear as dark, non-perfused zones, which helps quantify the degree of ischemia and predict progression risk. Neovascularization is confirmed by irregular dye leakage from the new vessels. This test is not used for routine screening but becomes essential when planning treatment or when the severity of disease is uncertain on clinical exam alone.

OCT has become indispensable for detecting and monitoring diabetic macular edema. It provides cross-sectional imaging of the retina and can measure retinal thickness with micrometer precision. A vignette describing central vision loss in a diabetic patient with macular thickening on OCT points directly to DME.

4. Management and Treatment

Clinical Scenario	Treatment	Key Details
All stages	Glycemic control, blood pressure control, lipid management	Target HbA1c < 7%; BP < 130/80 mmHg; statins as indicated
Mild to Moderate NPDR without DME	Observation with annual screening	No ophthalmic intervention needed; optimize systemic risk factors
Severe NPDR	Close monitoring (every 2-4 months); consider early panretinal photocoagulation	High conversion risk to PDR
Proliferative Diabetic Retinopathy	Panretinal (scatter) photocoagulation (PRP) and/or anti-VEGF intravitreal injections	PRP destroys ischemic retina to reduce VEGF drive; anti-VEGF (bevacizumab, ranibizumab, aflibercept) causes neovascular regression
Diabetic Macular Edema	Anti-VEGF intravitreal injections (first-line); intravitreal corticosteroids (second-line); focal/grid laser photocoagulation	Anti-VEGF given monthly until stable, then extended intervals
Vitreous hemorrhage (non-clearing)	Pars plana vitrectomy	Surgical removal of blood and fibrovascular tissue; also for tractional retinal detachment threatening the macula

Systemic optimization is the foundation at every stage. The DCCT (Type 1) and UKPDS (Type 2) trials demonstrated that intensive glycemic control reduces the risk of developing and progressing retinopathy. Blood pressure control is equally important; the ACCORD Eye study confirmed that even moderate hypertension accelerates retinal disease.

For proliferative disease, panretinal photocoagulation has been the standard of care for decades. PRP works by deliberately destroying peripheral ischemic retina with hundreds of laser burns, thereby reducing the total retinal oxygen demand and lowering VEGF production. The trade-off is loss of peripheral and night vision, which is why it is reserved for proliferative disease or severe NPDR at high risk of progression.

Anti-VEGF therapy has transformed management. For DME, intravitreal injections of agents like aflibercept (2 mg every 4 weeks for 5 doses, then every 8 weeks) or ranibizumab (0.3 mg monthly) are now first-line. For PDR, anti-VEGF injections are increasingly used as an alternative or adjunct to PRP, particularly in patients where PRP-related visual field loss would be functionally unacceptable.

Intravitreal corticosteroids (dexamethasone implant, fluocinolone acetonide implant) are second-line options for DME, particularly in pseudophakic patients. Their use in phakic patients is limited by the risk of cataract progression and steroid-induced glaucoma.

Vitrectomy is indicated when vitreous hemorrhage does not clear spontaneously (typically observed for 1-3 months), or when tractional retinal detachment involves or threatens the macula.

5. Differential Diagnosis and Distractors

Differential	Why It Is Confusing	Key Discriminator
Hypertensive retinopathy	Also causes cotton-wool spots, hemorrhages, and hard exudates on fundoscopy	Hypertensive retinopathy shows arteriovenous nicking, copper/silver wiring, and flame-shaped hemorrhages (not dot-and-blot); microaneurysms are uncommon; no neovascularization
Central retinal vein occlusion (CRVO)	Presents with sudden painless vision loss and retinal hemorrhages	CRVO produces a dramatic "blood and thunder" fundus with diffuse flame hemorrhages in all quadrants, dilated tortuous veins, and disc edema; typically unilateral and acute
Central retinal artery occlusion (CRAO)	Sudden painless vision loss in a patient with vascular risk factors	CRAO shows a pale/white retina with a cherry-red spot at the macula; no hemorrhages; acute presentation
Retinal detachment	Floaters and visual field loss overlap with vitreous hemorrhage from PDR	Retinal detachment presents with "curtain falling over vision" and photopsia (flashing lights); no diabetic fundoscopic changes unless tractional
Papilledema	Disc swelling may mimic disc neovascularization at a glance	Papilledema is bilateral, associated with elevated intracranial pressure symptoms (headache, transient visual obscurations, pulsatile tinnitus); no microaneurysms or hemorrhages in the pattern of DR
Sickle cell retinopathy	Also causes neovascularization and vitreous hemorrhage	Occurs in sickle cell disease (especially HbSC); neovascularization has a characteristic "sea fan" pattern at the peripheral retina

6. Traps and High-Yield Pearls

The most common testing trap with diabetic retinopathy involves confusing the screening timelines. Students frequently apply the Type 1 screening rule (5 years after diagnosis) to Type 2 patients, missing that Type 2 requires screening at the time of diagnosis because the true onset of hyperglycemia is unknown.

A second frequent error is treating DME as though it only occurs in advanced disease. Vignettes will describe a patient with mild NPDR and central vision loss, and students will dismiss macular edema because the retinopathy stage seems "too early." DME can occur at any stage, and its presence independently dictates treatment with anti-VEGF therapy regardless of the NPDR severity.

Another trap involves the management hierarchy. When a vignette presents a diabetic patient with new neovascularization, the tested answer is panretinal photocoagulation or anti-VEGF injections. Students sometimes incorrectly select "tighter glucose control" as the best next step. While glycemic optimization is always important, it is not sufficient as the sole intervention once proliferative disease has developed. Conversely, a patient with only mild NPDR does not need laser or injections; the correct answer in that scenario is observation and systemic risk factor control.

Finally, be aware that rapid improvement in glycemic control can paradoxically worsen retinopathy in the short term. A vignette describing a patient whose HbA1c dropped from 12% to 7% over a few months and who now has worsening retinal findings is testing this concept. The mechanism involves sudden shifts in retinal blood flow autoregulation. This does not mean glycemic control should be avoided; it means the patient needs closer ophthalmic follow-up during the transition period.

The core competency being tested across all diabetic retinopathy questions is the ability to stage the disease correctly on fundoscopy, match each stage to the appropriate intervention, and recognize DME as an independent treatment-driving entity at any point in the disease course.

1e:["$","$L2d",null,{"article":{"id":"84f97d05-c311-44dd-abf4-f706526a3d6a","title":"Retinopati Diabetikum","content":"$2e","category":"Oftalmologi","created_at":"2026-05-13T12:39:55.421885+00:00","status":"published","subcategory":null},"questionCount":14,"sections":[{"id":"section-pathophysiology","num":"01","title":"Pathophysiology"},{"id":"section-classification-and-clinical-manifestation","num":"02","title":"Classification and Clinical Manifestation"},{"id":"section-diagnostic-workup","num":"03","title":"Diagnostic Workup"},{"id":"section-management-and-treatment","num":"04","title":"Management and Treatment"},{"id":"section-differential-diagnosis-and-distractors","num":"05","title":"Differential Diagnosis and Distractors"},{"id":"section-traps-and-high-yield-pearls","num":"06","title":"Traps and High-Yield Pearls"}],"hasSummaryTable":true}]